Share This Page
Suppliers and packagers for CIPRO HC
✉ Email this page to a colleague
CIPRO HC
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Sandoz | CIPRO HC | ciprofloxacin hydrochloride; hydrocortisone | SUSPENSION/DROPS;OTIC | 020805 | NDA | A-S Medication Solutions | 50090-6043-0 | 10 mL in 1 BOTTLE (50090-6043-0) | 1999-03-15 |
| Sandoz | CIPRO HC | ciprofloxacin hydrochloride; hydrocortisone | SUSPENSION/DROPS;OTIC | 020805 | NDA | A-S Medication Solutions | 50090-7631-0 | 1 BOTTLE in 1 CARTON (50090-7631-0) / 10 mL in 1 BOTTLE | 1999-03-15 |
| Sandoz | CIPRO HC | ciprofloxacin hydrochloride; hydrocortisone | SUSPENSION/DROPS;OTIC | 020805 | NDA | Sandoz Inc | 66758-087-70 | 1 BOTTLE in 1 CARTON (66758-087-70) / 10 mL in 1 BOTTLE | 1999-03-15 |
| Sandoz | CIPRO HC | ciprofloxacin hydrochloride; hydrocortisone | SUSPENSION/DROPS;OTIC | 020805 | NDA | RedPharm Drug | 67296-2065-1 | 10 mL in 1 BOTTLE (67296-2065-1) | 1999-03-15 |
| Sandoz | CIPRO HC | ciprofloxacin hydrochloride; hydrocortisone | SUSPENSION/DROPS;OTIC | 020805 | NDA | Asclemed USA, Inc. | 76420-273-10 | 10 mL in 1 BOTTLE (76420-273-10) | 1999-03-15 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: CIPRO HC
Introduction
CIPRO HC, a combination medication containing ciprofloxacin and hydrocortisone, is widely prescribed for bacterial infections complemented by anti-inflammatory benefits. Its formulation provides clinicians with an effective treatment in various infections, particularly in dermatology and otolaryngology. As demand for CIPRO HC persists globally, reliable suppliers and manufacturers become pivotal for healthcare providers, pharmacies, and distributors seeking consistent quality, regulatory compliance, and competitive pricing.
This analysis explores the primary suppliers and manufacturing sources of CIPRO HC, detailing their market presence, supply chain position, and strategic importance within the pharmaceutical landscape.
Overview of CIPRO HC
CIPRO HC combines the broad-spectrum antibiotic ciprofloxacin, a fluoroquinolone, with hydrocortisone, a corticosteroid. This formulation aims to treat infections that involve inflammation and require antimicrobial action. The drug is typically supplied as topical ointments, ear drops, or ophthalmic preparations, with manufacturing predominantly concentrated in regions with robust pharmaceutical industries such as India, China, the United States, and Europe.
Given its formulation, key suppliers must meet stringent quality standards enforced by international regulatory authorities like the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other national agencies.
Major Manufacturers and Suppliers of CIPRO HC
1. Cipla Limited (India)
Cipla is a dominant player in the global pharmaceutical industry, especially known for its extensive portfolio of generic medications. The company manufactures CIPRO HC in various formulations, including topical ointments and ear drops, catering to domestic and international markets.
- Market Presence: Cipla holds a significant share of the Indian market and exports to more than 80 countries worldwide, including the United States, Europe, and emerging markets.
- Regulatory Compliance: Cipla’s manufacturing facilities adhere to WHO-GMP standards and have received approvals from major regulatory authorities including the FDA and EMA.
- Supply Capacity: With multiple manufacturing units and a global distribution network, Cipla can meet high-volume demands for CIPRO HC.
2. Mylan (Now part of Viatris) (United States/Global)
Viatris, formed after the merger of Mylan and Pfizer’s Upjohn unit, is a leading multinational supplier of generic medicines, including antimicrobial agents such as ciprofloxacin formulations.
- Product Portfolio: While primarily focused on oral and injectable ciprofloxacin, Viatris also produces topical formulations, with CIPRO HC being a critical part of its pipeline.
- Regulatory Approvals: Their manufacturing complies with cGMP standards, with facilities certified by the FDA and other regulators.
- Global Reach: As a major supplier in North America and Europe, Viatris supplies both branded and generic CIPRO HC to hospitals and pharmacies.
3. Dr. Reddy’s Laboratories (India)
Another prominent Indian pharmaceutical manufacturer, Dr. Reddy’s produces various dermatological and antimicrobial drugs, including CIPRO HC ointments and drops.
- Market Strategy: Focused on both domestic and export markets, with a strong footprint in Latin America, Southeast Asia, and Africa.
- Regulatory Status: Their manufacturing facilities are inspected regularly and are approved by global regulators, ensuring compliance and quality.
- Manufacturing Capacity: Capable of large-scale production, ensuring supply continuity.
4. Sun Pharmaceutical Industries Ltd. (India)
Sun Pharma ranks among the top global generic manufacturers, supplying CIPRO HC formulations primarily to emerging markets.
- Product Certification: Their facilities comply with cGMP and hold approvals from the FDA, EMA, and other regulators.
- Supply Chain: Known for robust distribution networks in Asia, Africa, and Latin America, ensuring competitive access.
5. Local and Regional Manufacturers
Apart from global giants, numerous regional and local companies in countries like China, Brazil, and Turkey manufacture CIPRO HC formulations. These entities often focus on regional markets and may offer more competitive pricing but face varying regulatory oversight.
Supply Chain Dynamics and Quality Considerations
The supply of CIPRO HC hinges on manufacturing quality, regulatory certifications, and global distribution capabilities. Given its classification as a prescription medication, manufacturers must adhere to rigorous Good Manufacturing Practices (GMP). Regulatory oversight from authorities such as the FDA (USA), EMA (Europe), and national agencies in emerging markets influence market access and supply reliability.
Furthermore, geographic diversification reduces supply chain vulnerabilities. The recent global disruptions, including supply chain interruptions caused by the COVID-19 pandemic, underscore the importance of multiple suppliers and resilient logistics networks.
Regulatory and Compliance Factors
Suppliers operating globally must maintain compliance with local and international regulations to prevent disruptions. Certifications from organizations such as the International Organization for Standardization (ISO), certification of manufacturing facilities under cGMP, and specific approvals for CIPRO HC formulations are critical benchmarks for trusted suppliers.
Quality assurance extends beyond manufacturing; packaging, labeling, and distribution channels must meet regulatory standards tailored to each market.
Emerging Trends and Strategic Considerations
- Generic Market Expansion: As patent protections for original formulations expire in key markets, generic manufacturers increasingly enter the CIPRO HC space.
- Regulatory Harmonization: Initiatives like the ICH guidelines facilitate smoother approval processes across jurisdictions, enabling quicker market entry for reputable suppliers.
- Supply Chain Transparency: Bigger suppliers adopt supplier qualification protocols and traceability systems to ensure product integrity.
- Biopharmaceutical Innovation: Although CIPRO HC is a well-established formulation, ongoing R&D aims to enhance formulations, stability, and delivery mechanisms, influencing supplier capabilities and investments.
Conclusion
The supply landscape for CIPRO HC revolves around well-established, internationally compliant manufacturers with extensive distribution networks. Key players like Cipla, Viatris, Dr. Reddy’s, and Sun Pharma dominate global markets, supported by their longstanding regulatory compliance, reliable manufacturing capacity, and strategic geographic positioning.
For healthcare providers and distributors, selecting suppliers with validated GMP standards, regulatory approvals, and robust supply chain management ensures consistent, high-quality access to CIPRO HC. As the pharmaceutical market evolves, diversified sourcing strategies and continued regulatory vigilance remain essential to maintaining supply stability.
Key Takeaways
- Leading global suppliers of CIPRO HC include Cipla, Viatris (formerly Mylan), Dr. Reddy’s, and Sun Pharma.
- Regulatory compliance, including GMP certification and official approvals, is critical for supply reliability.
- Geographic diversification minimizes supply chain vulnerabilities amid global disruptions.
- The global generic drug market for CIPRO HC is expanding, driven by patent expirations and regional demand.
- Maintaining high-quality standards and transparency enhances trust and ensures sustained supply.
Frequently Asked Questions
Q1: Are there significant regional differences in CIPRO HC suppliers?
Yes. While global giants dominate international markets, regional manufacturers primarily supply local markets, influenced by regulatory approvals, cost, and distribution networks.
Q2: How can healthcare providers ensure the authenticity of CIPRO HC supplies?
By sourcing from approved and certified suppliers, verifying GMP certifications, and ensuring traceability through reliable supply chain documentation.
Q3: What regulatory standards should suppliers of CIPRO HC meet?
Suppliers should comply with cGMP standards, possess approvals from major agencies like the FDA or EMA, and adhere to international quality controls.
Q4: How does patent expiry influence CIPRO HC supply?
Patent expiration allows generic manufacturers to produce equivalent formulations, increasing supply options and potentially reducing costs.
Q5: Is there ongoing innovation related to CIPRO HC formulations?
While CIPRO HC formulations are well established, ongoing research seeks to improve delivery mechanisms, formulation stability, and broaden applications, impacting future supplier capacities.
Sources:
[1] Cipla Ltd. Corporate Website. (n.d.)
[2] Viatris (formerly Mylan) Official Website. (n.d.)
[3] Dr. Reddy’s Laboratories Annual Report. (2022)
[4] Sun Pharmaceutical Industries Ltd. Regulatory Filings. (2022)
[5] Global Generic Drug Market Analysis, IQVIA Reports. (2023)
More… ↓
